Himension Capital Singapore PTE. LTD. Buys Shares of 85,164 ARK Genomic Revolution ETF $ARKG

Himension Capital Singapore PTE. LTD. purchased a new position in ARK Genomic Revolution ETF (BATS:ARKG) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 85,164 shares of the company’s stock, valued at approximately $2,250,000.

Other hedge funds also recently made changes to their positions in the company. Ascentis Independent Advisors bought a new position in ARK Genomic Revolution ETF in the first quarter valued at $26,000. PNC Financial Services Group Inc. lifted its stake in ARK Genomic Revolution ETF by 53.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,088 shares of the company’s stock worth $29,000 after purchasing an additional 378 shares during the last quarter. Sunbelt Securities Inc. lifted its stake in ARK Genomic Revolution ETF by 734.3% during the third quarter. Sunbelt Securities Inc. now owns 1,118 shares of the company’s stock worth $31,000 after purchasing an additional 984 shares during the last quarter. AlphaCore Capital LLC purchased a new position in shares of ARK Genomic Revolution ETF in the 4th quarter worth about $39,000. Finally, Hilton Head Capital Partners LLC boosted its holdings in shares of ARK Genomic Revolution ETF by 161.4% in the 1st quarter. Hilton Head Capital Partners LLC now owns 1,537 shares of the company’s stock worth $41,000 after purchasing an additional 949 shares in the last quarter.

ARK Genomic Revolution ETF Trading Up 3.3%

Shares of ARK Genomic Revolution ETF stock opened at $39.56 on Wednesday. The business’s 50-day moving average price is $36.26 and its 200-day moving average price is $31.73. ARK Genomic Revolution ETF has a 12 month low of $22.73 and a 12 month high of $44.47.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.